Acoramidis (AG10) is an orally bioavailable, selective TTR stabilizer that is currently being assessed for effects on mortality and hospitalization for cardiovascular causes in subjects with transthyretin amyloid cardiomyopathy in an ongoing phase 3 trial, with topline data expected in mid-2023. Here, TTR is linked to prealbumin measurement.